Comprehensive research guide to cognitive peptides Selank and Semax. Mechanisms of action, BDNF modulation, anxiolytic effects, and neuroimaging evidence with PubMed citations.
Last updated Jun 11, 2026·9 min read
The brain’s capacity to adapt, learn, and regulate its own emotional state depends on a delicate interplay of neurotrophic factors, neurotransmitter systems, and inflammatory signaling. When this balance is disrupted — by chronic stress, neuroinflammation, or aging — cognitive performance suffers.
Two synthetic heptapeptides have attracted particular research interest in this domain: Selank Selank synthetic heptapeptide derived from tuftsin Tuftsin-derived anxiolytic peptide studied for immune modulation and stress response and Semax Semax synthetic heptapeptide derived from adrenocorticotropic hormone ACTH-derived nootropic peptide studied for BDNF modulation and cognitive performance . Both emerged from Russian neuroscience research programs in the 1980s and 1990s, both are derived from endogenous peptide precursors, and both are administered intranasally to access the central nervous system. Yet their mechanisms of action are strikingly different.
**Selank Selank synthetic heptapeptide derived from tuftsin Tuftsin-derived anxiolytic peptide studied for immune modulation and stress response ** is a tuftsin analog that researchers study primarily for its anxiolytic and immunomodulatory properties. Its interaction with the GABAergic system and its ability to modulate pro-inflammatory cytokines position it at the intersection of stress response and cognitive function PMID: 21833148 .
**Semax Semax synthetic heptapeptide derived from adrenocorticotropic hormone ACTH-derived nootropic peptide studied for BDNF modulation and cognitive performance ** is an ACTH(4-10) fragment studied for its effects on brain-derived neurotrophic factor (BDNF) and neuroplasticity. Research suggests it may directly enhance the molecular machinery underlying learning and memory through TrkB receptor activation PMID: 16996037 .
A 2020 functional connectivity study directly compared both peptides in 52 healthy volunteers using resting-state fMRI — providing the first neuroimaging evidence that these compounds produce distinct yet potentially complementary effects on brain networks involved in emotion and cognition PMID: 32342318 .
Both compounds remain classified as research peptides. The evidence presented here reflects published preclinical and clinical literature and is intended as an educational resource for researchers — not as guidance for human use, treatment, or diagnosis.
I.Overview
Cognitive function is not a single process but an emergent property of multiple interacting brain systems — attention, working memory, emotional regulation, executive control, and long-term memory consolidation. Each of these systems depends on distinct neural circuits, neurotransmitter balances, and molecular signaling pathways.
Research into peptide-based approaches to cognitive support has focused on two broad strategies. The first targets neurotrophic signaling — enhancing the brain’s own growth and repair mechanisms through molecules like BDNF, which promotes synaptic plasticity, neuronal survival, and the formation of new neural connections. The second targets the stress-cognition interface — modulating the inflammatory and hormonal responses that, when chronically activated, degrade cognitive performance.
Selank Selank synthetic heptapeptide derived from tuftsin Tuftsin-derived anxiolytic peptide studied for immune modulation and stress response and Semax Semax synthetic heptapeptide derived from adrenocorticotropic hormone ACTH-derived nootropic peptide studied for BDNF modulation and cognitive performance represent these two strategies respectively. Selank works primarily through the stress-cognition axis: its anxiolytic effects, mediated through GABAergic modulation and enkephalinase inhibition, may reduce the cognitive burden of chronic anxiety and neuroinflammation PMID: 21833148 . Semax works through the neurotrophic axis: its upregulation of BDNF and activation of TrkB receptors may directly enhance the synaptic plasticity mechanisms that underlie learning and memory PMID: 16996037 .
The distinction matters. Chronic stress and elevated pro-inflammatory cytokines (particularly IL-6 and TNF-alpha) are well-established suppressors of hippocampal BDNF expression. This means that stress-related neuroinflammation actively undermines the very neuroplastic mechanisms that Semax Semax synthetic heptapeptide derived from adrenocorticotropic hormone ACTH-derived nootropic peptide studied for BDNF modulation and cognitive performance is studied for enhancing. In theory, addressing both pathways simultaneously — reducing the inflammatory burden while promoting neurotrophic signaling — could produce effects that neither approach achieves alone.
This mechanistic complementarity is the scientific basis for studying these peptides as a combination, as explored in the Cognitive Stack research context.
**Selank Selank synthetic heptapeptide derived from tuftsin Tuftsin-derived anxiolytic peptide studied for immune modulation and stress response ** is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from tuftsin — an endogenous immunomodulatory peptide originally isolated from immunoglobulin G. The molecular weight is 751.9 Da, and its short plasma half-life makes intranasal delivery the preferred administration route, as it improves direct access to the central nervous system while avoiding first-pass metabolism.
Selank Selank synthetic heptapeptide derived from tuftsin Tuftsin-derived anxiolytic peptide studied for immune modulation and stress response was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, where researchers sought to create a stable analog of tuftsin that retained its immunomodulatory properties while adding anxiolytic activity. The resulting molecule has been studied in multiple clinical trials in Russia, where it is approved for clinical use in anxiety-related conditions.
The anxiolytic mechanism of Selank Selank synthetic heptapeptide derived from tuftsin Tuftsin-derived anxiolytic peptide studied for immune modulation and stress response involves multiple pathways. Research indicates that it inhibits enkephalinase — an enzyme that degrades endogenous opioid peptides such as leu-enkephalin — potentially enhancing the body’s natural calming mechanisms PMID: 21833148 . A clinical study comparing Selank to medazepam in 62 patients with generalized anxiety disorder found that Selank produced anxiolytic effects comparable to the benzodiazepine while additionally demonstrating antiasthenic and psychostimulant properties that medazepam lacked PMID: 18454096 .
Cytokine modulation is a second key mechanism. A 2020 study demonstrated that Selank Selank synthetic heptapeptide derived from tuftsin Tuftsin-derived anxiolytic peptide studied for immune modulation and stress response can reduce the concentration of pro-inflammatory cytokines IL-1-beta, IL-6, and TNF-alpha, as well as TGF-beta1, practically restoring these markers to control values under inflammatory conditions PMID: 32621722 . This is significant for cognitive research because chronic elevation of IL-6 and TNF-alpha has been associated with impaired hippocampal function and reduced BDNF expression — creating a mechanistic link between Selank’s anti-inflammatory activity and its potential cognitive relevance.
GABAergic system interaction is the third major mechanism studied. Selank Selank synthetic heptapeptide derived from tuftsin Tuftsin-derived anxiolytic peptide studied for immune modulation and stress response ’s interaction with GABA-A receptors is believed to contribute to its anxiolytic effects, though the precise binding dynamics differ from those of classical benzodiazepines. This distinction is research-relevant because it suggests a different side-effect profile — Selank does not appear to produce the sedation, dependence, or cognitive impairment associated with long-term benzodiazepine use PMID: 21833148 .
In the 2020 fMRI connectivity study PMID: 32342318 , Selank Selank synthetic heptapeptide derived from tuftsin Tuftsin-derived anxiolytic peptide studied for immune modulation and stress response was observed to produce specific effects on amygdala-temporal cortex connectivity — brain regions central to emotional processing and fear regulation. This neuroimaging signature is consistent with its documented anxiolytic mechanisms and provides direct evidence that intranasal Selank modulates functional brain connectivity in humans.
**Semax Semax synthetic heptapeptide derived from adrenocorticotropic hormone ACTH-derived nootropic peptide studied for BDNF modulation and cognitive performance ** is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the adrenocorticotropic hormone (ACTH), specifically the ACTH(4-10) fragment with a C-terminal Pro-Gly-Pro extension that enhances enzymatic stability. Its molecular weight is 813.9 Da. Like Selank Selank synthetic heptapeptide derived from tuftsin Tuftsin-derived anxiolytic peptide studied for immune modulation and stress response , it is administered intranasally to access the central nervous system.
Semax Semax synthetic heptapeptide derived from adrenocorticotropic hormone ACTH-derived nootropic peptide studied for BDNF modulation and cognitive performance was developed at the V.V. Zakusov Research Institute of Pharmacology in Moscow during the 1980s. It is approved in Russia for clinical use in conditions including cognitive impairment, optic nerve atrophy, and as a neuroprotective agent following stroke. Unlike its parent hormone ACTH, Semax does not affect cortisol levels — its cognitive and neuroprotective effects are mediated through entirely separate pathways.
BDNF upregulation is the most extensively studied mechanism of Semax Semax synthetic heptapeptide derived from adrenocorticotropic hormone ACTH-derived nootropic peptide studied for BDNF modulation and cognitive performance . A seminal 2006 study demonstrated that intranasal Semax increased BDNF protein levels by up to 1.4-fold and TrkB receptor phosphorylation by 1.6-fold in the rat hippocampus — the brain region most critical for learning and memory — within 3 hours of administration PMID: 16996037 . Earlier work had shown that Semax stimulates BDNF expression across multiple brain regions, including the cortex and hippocampus, in a dose-dependent manner PMID: 14556513 .
TrkB receptor activation is the downstream consequence of BDNF upregulation. TrkB is the primary receptor through which BDNF exerts its neuroplastic effects — activating intracellular cascades (MAPK/ERK, PI3K/Akt, PLC-gamma) that promote synaptic strengthening, dendritic growth, and neuronal survival. By enhancing both BDNF availability and TrkB phosphorylation, Semax Semax synthetic heptapeptide derived from adrenocorticotropic hormone ACTH-derived nootropic peptide studied for BDNF modulation and cognitive performance may amplify the brain’s endogenous neuroplastic signaling PMID: 16996037 .
Neurotransmitter modulation adds a third dimension. Research suggests Semax Semax synthetic heptapeptide derived from adrenocorticotropic hormone ACTH-derived nootropic peptide studied for BDNF modulation and cognitive performance modulates serotonergic and dopaminergic systems, which are central to attention, motivation, and executive function PMID: 25313017 . This multi-system activity may explain why Semax has been studied not only for memory and learning but also for mood support and attention-related endpoints.
Neuroimaging evidence in humans includes a 2018 pilot fMRI study in 24 healthy subjects showing that intranasal Semax Semax synthetic heptapeptide derived from adrenocorticotropic hormone ACTH-derived nootropic peptide studied for BDNF modulation and cognitive performance (1.2 mg total dose) increased resting fMRI signal in the default mode network relative to placebo PMID: 30225715 . In the 2020 comparative fMRI study PMID: 32342318 , Semax produced distinct connectivity changes from Selank Selank synthetic heptapeptide derived from tuftsin Tuftsin-derived anxiolytic peptide studied for immune modulation and stress response , with effects more prominent in regions associated with cognitive processing rather than emotional regulation — consistent with its BDNF-mediated mechanism.
The scientific rationale for combining Selank Selank synthetic heptapeptide derived from tuftsin Tuftsin-derived anxiolytic peptide studied for immune modulation and stress response and Semax Semax synthetic heptapeptide derived from adrenocorticotropic hormone ACTH-derived nootropic peptide studied for BDNF modulation and cognitive performance rests on their apparently non-overlapping mechanisms acting on complementary aspects of cognitive function.
**Selank Selank synthetic heptapeptide derived from tuftsin Tuftsin-derived anxiolytic peptide studied for immune modulation and stress response ** modulates the brain’s stress and inflammatory systems. Research indicates it may inhibit enkephalinase, enhancing endogenous opioid peptide activity PMID: 21833148 ; reduce pro-inflammatory cytokines IL-6, TNF-alpha, and IL-1-beta PMID: 32621722 ; and produce anxiolytic effects through GABAergic modulation PMID: 21833148 . These mechanisms address the stress-cognition interface — the well-documented pathway through which chronic anxiety and neuroinflammation impair cognitive performance.
**Semax Semax synthetic heptapeptide derived from adrenocorticotropic hormone ACTH-derived nootropic peptide studied for BDNF modulation and cognitive performance ** operates through entirely different molecular targets. It upregulates BDNF protein and TrkB receptor phosphorylation in the hippocampus PMID: 16996037 , modulates serotonin and dopamine neurotransmitter systems PMID: 25313017 , and enhances default mode network activity in healthy volunteers PMID: 30225715 . These mechanisms address the neuroplastic machinery directly — the molecular infrastructure of learning and memory.
The complementarity is mechanistically compelling. Chronic stress and neuroinflammation are well-established suppressors of hippocampal BDNF expression. This means that Selank Selank synthetic heptapeptide derived from tuftsin Tuftsin-derived anxiolytic peptide studied for immune modulation and stress response ’s anti-inflammatory and anxiolytic activity may create more favorable conditions for Semax Semax synthetic heptapeptide derived from adrenocorticotropic hormone ACTH-derived nootropic peptide studied for BDNF modulation and cognitive performance ’s neuroplastic effects to operate. In research terms: one compound may reduce the noise while the other amplifies the signal.
The 2020 functional connectivity study PMID: 32342318 provided the first direct neuroimaging evidence that both compounds can be studied simultaneously in the same experimental framework. In 52 healthy participants, resting-state fMRI revealed that Selank Selank synthetic heptapeptide derived from tuftsin Tuftsin-derived anxiolytic peptide studied for immune modulation and stress response and Semax Semax synthetic heptapeptide derived from adrenocorticotropic hormone ACTH-derived nootropic peptide studied for BDNF modulation and cognitive performance produced distinct yet overlapping effects on brain connectivity — Selank’s effects centered on amygdala-temporal cortex networks (emotional processing), while Semax’s effects were more prominent in cognitive-processing regions. The study identified both general effects (shared connectivity changes) and compound-specific signatures.
It is essential to note: no clinical trial has tested this specific combination in humans as a defined intervention. The synergy rationale is extrapolated from independent studies on each compound plus the single comparative fMRI study. Researchers should treat the evidence as exploratory.
IV.Frequently Asked Questions
Frequently Asked Questions
Selank is a tuftsin-derived heptapeptide studied primarily for anxiolytic and immunomodulatory effects — it works through GABAergic modulation, enkephalinase inhibition, and pro-inflammatory cytokine reduction [PMID: 21833148, PMID: 32621722]. Semax is an ACTH(4-10) fragment studied for cognitive enhancement — it works through BDNF upregulation, TrkB receptor activation, and neurotransmitter modulation [PMID: 16996037, PMID: 25313017]. In short: Selank addresses the stress and inflammation that impair cognition; Semax targets the neuroplastic machinery that underlies learning and memory.
The most relevant evidence is a 2020 resting-state fMRI study in 52 healthy volunteers that directly compared both peptides [PMID: 32342318]. It found that Selank and Semax produced distinct yet overlapping effects on brain connectivity — Selank primarily affected amygdala-temporal cortex networks (emotional processing), while Semax affected cognitive-processing regions more prominently. However, this study characterized individual effects rather than testing the combination as a single intervention. No controlled human trial has tested Selank + Semax together as a defined protocol.
Selank interacts with the GABAergic system but through mechanisms that differ from classical benzodiazepines. A clinical study in 62 patients with generalized anxiety disorder found that Selank produced anxiolytic effects comparable to medazepam but additionally showed antiasthenic and psychostimulant properties — effects opposite to the sedation typical of benzodiazepines [PMID: 18454096]. Selank also inhibits enkephalinase, enhancing endogenous opioid peptide activity rather than directly binding GABA-A receptor sites the way benzodiazepines do.
BDNF (brain-derived neurotrophic factor) is a protein that promotes the survival, growth, and differentiation of neurons. It is particularly concentrated in the hippocampus — the brain region most critical for learning and memory. Research has shown that Semax can increase hippocampal BDNF protein levels by up to 1.4-fold and TrkB receptor phosphorylation by 1.6-fold within 3 hours of intranasal administration in animal models [PMID: 16996037]. Reduced BDNF levels have been associated with cognitive decline, depression, and neurodegenerative conditions.
Research suggests a mechanistic link. Chronic elevation of pro-inflammatory cytokines — particularly IL-6 and TNF-alpha — is associated with impaired hippocampal function and suppressed BDNF expression. A 2020 study demonstrated that Selank can reduce IL-1-beta, IL-6, TNF-alpha, and TGF-beta1 concentrations, practically restoring them to control values [PMID: 32621722]. By reducing neuroinflammatory burden, Selank may theoretically create more favorable conditions for the neuroplastic processes that Semax is studied for enhancing.
Both compounds have more human clinical data than most research peptides, primarily from Russian clinical programs. Selank has been studied in controlled clinical trials for generalized anxiety disorder [PMID: 18454096]. Semax has been studied in healthy volunteers using fMRI [PMID: 30225715]. The 2020 comparative fMRI study [PMID: 32342318] included 52 healthy human volunteers. However, much of the mechanistic evidence comes from animal models and cell culture studies.
In Russia, both compounds are approved for clinical use — Selank for anxiety-related conditions and Semax for cognitive impairment and optic nerve atrophy. Outside Russia, both are classified as research-only compounds. They are not approved by the FDA, EMA, or MHRA for any therapeutic indication.
Both compounds are primarily studied via intranasal delivery, which provides direct access to the central nervous system through the olfactory and trigeminal nerve pathways. Subcutaneous injection has also been used in some studies. Both peptides have short half-lives (measured in minutes), which is why consistent daily administration is typical in research protocols.
V.Summary
Selank Selank synthetic heptapeptide derived from tuftsin Tuftsin-derived anxiolytic peptide studied for immune modulation and stress response and Semax Semax synthetic heptapeptide derived from adrenocorticotropic hormone ACTH-derived nootropic peptide studied for BDNF modulation and cognitive performance represent two distinct but potentially complementary approaches to supporting cognitive function at the molecular level. Each has a body of clinical research — primarily from Russian neuroscience programs — each works through a different mechanism, and each targets a different aspect of the brain’s cognitive architecture.
What the research literature demonstrates is that both compounds are biologically active with documented effects in clinical and preclinical settings. Selank Selank synthetic heptapeptide derived from tuftsin Tuftsin-derived anxiolytic peptide studied for immune modulation and stress response ’s anxiolytic and anti-inflammatory mechanisms address the stress-cognition interface. Semax Semax synthetic heptapeptide derived from adrenocorticotropic hormone ACTH-derived nootropic peptide studied for BDNF modulation and cognitive performance ’s BDNF/TrkB modulation targets the molecular infrastructure of neuroplasticity directly. The 2020 fMRI study provided the first neuroimaging evidence that both compounds produce identifiable, distinct neural signatures in healthy humans.
What the literature does not yet establish is whether combining these compounds produces clinically meaningful cognitive benefits beyond what either achieves alone — a question that only controlled human trials can answer.
For more on the specific combination rationale, see the Cognitive Stack guide. For the individual compound profiles, see [Selank Selank synthetic heptapeptide derived from tuftsin Tuftsin-derived anxiolytic peptide studied for immune modulation and stress response ](/en/compounds/selank/) and [Semax Semax synthetic heptapeptide derived from adrenocorticotropic hormone ACTH-derived nootropic peptide studied for BDNF modulation and cognitive performance ](/en/compounds/semax/). Primary literature is accessible through PubMed.
Selank synthetic heptapeptide derived from tuftsin Tuftsin-derived anxiolytic peptide studied for immune modulation and stress response ** is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from tuftsin — an endogenous immunomodulatory peptide originally isolated from immunoglobulin G. The molecular weight is 751.9 Da, and its short plasma half-life makes intranasal delivery the preferred administration route, as it improves direct access to the central nervous system while avoiding first-pass metabolism.